Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors
Citations Over TimeTop 20% of 2010 papers
Abstract
On the basis of the structures and activities of our previously identified non-nucleoside reverse transcriptase inhibitors (NNRTIs), we designed and synthesized two sets of derivatives, diarylpyridines (A) and diarylanilines (B), and tested their anti-HIV-1 activity against infection by HIV-1 NL4-3 and IIIB in TZM-bl and MT-2 cells, respectively. The results showed that most compounds exhibited potent anti-HIV-1 activity with low nanomolar EC50 values, and some of them, such as 13m, 14c, and 14e, displayed high potency with subnanomolar EC50 values, which were more potent than etravirine (TMC125, 1) in the same assays. Notably, these compounds were also highly effective against infection by multi-RTI-resistant strains, suggesting a high potential to further develop these compounds as a novel class of NNRTIs with improved antiviral efficacy and resistance profile.
Related Papers
- → Evaluating the Role of Etravirine in the Second-Line Antiretroviral Therapy After Failing an Initial Non-Nucleoside Reverse Transcriptase Inhibitor- Based Regimen in a Resource-Limited Setting§(2008)20 cited
- → Etravirine: Clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance(2010)8 cited
- Etravirine: A non-nucleoside reverse transcriptase inhibitor for the treatment of resistant HIV-1 infection(2008)
- Etravirine:a novel nonnucleoside reverse transcriptase inhibitor(2010)
- → Etravirine* [TMC 125], a next-generation non-nucleoside reverse transcriptase inhibitor, is effective in treatment-resistant patients with HIV-1 infections,(2006)